A Phase 3 interventional study of Fusidic Acid 1% and Placebo in Bacterial Conjunctivitis, sponsored by Baxis Pharmaceuticals, Inc.. Recruiting at 38 sites in United States. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Baxis Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Conjunctivitis, Bacterial with a site in United States — 2 open to participants now, 2 under way, 1 of them phase 3. Conjunctivitis, Bacterial · United States.
Among the 20 studies in Conjunctivitis, Bacterial with a site in United States, this one is the 11th largest by planned enrollment, is the only one that started in 2025, is one of 12 in phase 3, and was the 19th registered.
40 studies on the registry are indexed under Conjunctivitis, Bacterial; 2 are open to participants now.
Browse Conjunctivitis, Bacterial studies →2 of the 20 studies in Conjunctivitis, Bacterial with a site in United States are open now. Recruiting first, the newest first:
Senju USA, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 2 Conjunctivitis, Bacterial studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 13 · Phase 4 3
First in 2004; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 400 is above the median of 261 across 36 interventional studies indexed under Conjunctivitis, Bacterial.
Median enrollment 413 across the 20 interventional studies. Of the 18 that completed or were terminated, 13 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 20 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Baxis Pharmaceuticals, Inc. as lead sponsor.
Baxis Pharmaceuticals, Inc. has 1 study filed under Conjunctivitis, Bacterial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Conjunctivitis, Bacterial with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will instill one drop of fusidic acid 1% per eye twice a day (BID) for 7 days. Approximately 12 hours between doses is preferred, but BID administration takes precedence over precise timing
Drug: Fusidic Acid 1%
Participants will instill one drop of Placebo ophthalmic solution per eye BID for 7 days. Approximately 12 hours between doses is preferred, but BID administration takes precedence over precise timing
Drug: Placebo
Fusidic acid 1%
Placebo ophthalmic solution
Clinical Cure
Proportion of patients with a positive bacterial culture at Visit 1 (Day 1) who achieve clinical cure.
Time frame: Visit 2 (Day 4)
Microbial Eradication
Proportion of subjects with a positive bacterial culture at Visit 1 (Day 1) who achieve microbiological eradication.
Time frame: Visit 2 (Day 4)
Microbial Eradication
Proportion of subjects with a positive bacterial culture at Visit 1 (Day 1) who achieve microbiological eradication.
Time frame: Visit 3 (Day 8)
Clinical Cure
Proportion of patients with a positive bacterial culture at Visit 1 (Day 1) who achieve clinical cure.
Time frame: Visit 3 (Day 8)
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Mar 2026, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fusidic Acid